Non-specific microbicide product development: Then and now

Current HIV Research

Volumn 10, Issue 1, 2012, Pages 9-18

  Romano, Joseph W ^a   Robbiani, Melissa ^b   Doncel, Gustavo F ^c   Moench, Thomas ^d  

^a NWJ Group LLC   (United States)

^b POPULATION COUNCIL   (United States)

^c EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^d REPROTECT INC   (United States)

Author keywords

HIV; Microbicides; Prevention; Product development

Indexed keywords

ACIDFORM; AMPHORA; ANTIRETROVIRUS AGENT; C 31G; CARBOPOL 974P; CARRAGEENAN; CELLULOSE SULFATE; MICROBICIDE; MIV 150; NONOXINOL 9; PLACEBO; PRANEEM; PRO 2000; TENOFOVIR; UNCLASSIFIED DRUG; VIVAGEL;

ANTIVIRAL ACTIVITY; DISEASE TRANSMISSION; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; GENITAL SYSTEM DISEASE; HERPES SIMPLEX VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NEISSERIA GONORRHOEAE; NONHUMAN; PELVIC DISEASE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEXUALLY TRANSMITTED DISEASE; VAGINITIS; VIRUS TRANSMISSION;

ADMINISTRATION, TOPICAL; ANTI-INFECTIVE AGENTS, LOCAL; ANTI-RETROVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; HIV INFECTIONS; HUMANS; SURFACE-ACTIVE AGENTS;

EID: 84857135720     PISSN: 1570162X     EISSN: 18734251     Source Type: Journal    
DOI: 10.2174/157016212799304625     Document Type: Review

References (157)

1. Barré-Sinoussi F, Chermann JC, Rey F, et al. Isolation of a Tlymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983; 220: 868-871.
2. Popovic M, Sarngadharan MG, Read E, et al. Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science 1984; 224: 497-500.
3. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 36: 2209-2220.
4. Palmisano L, Vella S. A brief history of antiretroviral therapy of HIV infection: success and challenges. Ann Ist Super Sanita 2011;47: 44-48.
5. UNAIDS Report on the Global AIDS Epidemic, 2010.
6. Hodgen GD: HIV and Contraception: Research Priorities. In Heterosexual Transmission of AIDS, NJ Alexander, HL Gabelnick, JM Spieler (eds). New York, Wiley-Liss, 1990.
7. Elias CJ, Heise L: The development of microbicides: A new method of HIV prevention for women. New York, The Population Council, 1993.
8. Stein ZA. Vaginal microbicides and prevention of HIV infection. Lancet 1994; 343: 362-363.
9. Abu-Raddad LJ, Magaret AS, Celum C, et al. Genital herpes has played a more important role than any other sexually transmittedinfection in driving HIV prevalence in Africa. PLoS One 2008; 3(5): e2230.
10. Buttar HS, Swierenga SHH, Matula TI. Evaluation of the cytotoxicity and genotoxicity of the spermicides nonoxynol-9 and Octoxynol-9. ToxicolLett 1986; 1: 65-73.
11. Hicks DR, Martin LS, Getchell JP, et al. Inactivation of HTLVIII/ Lav infected cultures of normal human lymphocytes by nonoxynol-9 in vitro. Lancet 1985; 2: 1422-1423.
12. Malkovsky M, Newell A, Dalgleish AG. Inactivation of HIV by nonoxynol-9. Lancet 1988; 1: 645.
13. Singh B, Cutler JC, Utidjian HMD. Studies on the development of a vaginal preparation providing both prophylaxis against venereal disease and other genital infections and contraception. II. Effect in vitro of vaginal contraceptive and non-contraceptive preparations on Trepenemapallidum and Neisseria gonorrhoeae. Br J Vener Dis 1972; 48: 57-64.
14. Benes M, McCormick WM, Inhibition of growth of Chlamydia Trachomatis by nonoxynol-9 in vitro. Antimicrob Agents Chemother 1985; 27: 724-726.
15. Asculai SS, Weis MT, Rancourt MW, et al. Inactivation of herpes simplex viruses by nonionic surfactants. Antimicrob Agents Chemother 1978; 13: 686-690.
16. Miller CJ, Alexander NJ, Gettie A, et al. The effect of contraceptives containing nonoxynol-9 on the genital transmission of simian immunodeficiency virus in rhesus macaques. FertilSteril 1992; 259: 1851-1853.
17. Hiller SL, Moench T, Shattock R, Black R, Reichelderfer P, Veronese F. In vitro and In vivo: The story of nonoxynol-9. JAcquir Immune DeficSyndr 2005; 39: 1-8.
18. Vandebosch A, Goetghebeur E, Ramjee G, et al. Acceptability of COL-1492, a vaginal gel, among sex workers in one Asian and three African cities. Sex Transm Infect 2004; 80: 241-243.
19. Van Damme L, Chandeying V, Ramjee G, et al. Safety of multiple applications of COL-1492, a nonoxynol-9 vaginal gel, amongfemale sex workers. COL-1492 Phase II Study Group AIDS 2000; 14: 85-88.
20. Roddy RE, Zekeng L, Kelley R, et al. A controlled trial of nonoxynol 9 film to reduce male-to-female transmission of sexually transmitted diseases. New Eng J Med 1998; 339: 504-510.
21. Richardson BA, Lavreys L, Martin HL, et al. Evaluation of a lowdose Nonoxynol-9 gel for prevention of sexually transmitteddiseases. Sex Transm Dis 2001; 28: 394-400.
22. Van Damme L, Ramjee G, Vuuylsteke N, et al. Effectiveness ofCOL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission infemale sex workers: A randomized controlled trial. Lancet 2002; 360: 971-977.
23. Phillips DM, Sudol KM, Taylor CL, et al. Lubricants containing N-9 may enhance rectal transmission of HIV and other STIs. Contraception 2004; 70(2): 107-110.
24. Krebs FC, Miller SR, Malamud D, Howett MK, Wigdahl B. Inactivation of human immunodeficiency virus type 1 bynonoxynol-9, C31G, or an alkyl sulfate, sodium dodecyl sulfate. Antiviral Res 1999; 43: 157-173.
25. Krebs FC, Miller SR, Catalone BJ, et al. Sodium dodecyl sulfate and C31G as microbicidal alternatives to nonoxynol-9; comparative sensitivity of primary human vaginal keratinocytes. Antimicron Agents Chemother 2000; 1954-1960.
26. Wyrick PB, Knight ST, Gerbig DG Jr, et al. The microbicidal agent C31G inhibits Chlamydia trachomatis infectivity in vitro. Antimicrob Agents Chemother 1997; 41: 1335-1344.
27. Thompson KA, Malamud D, Storey BT. Assessment of the antimicrobial agent C31G as a spermicide: Comparison with nonoxynol-9. Contraception 1996; 53: 313-318.
28. Mauck CK, Frezieres RG, Walsh TL, et al. Male tolerance study of 1% C31G. Contraception 2004a; 70: 221-225.
29. Bax R, Douville K, McCormick D, et al. Microbicides-evaluating multiple formulations of C31G. Contraception 2002; 66(5): 365-368.
30. Mauck CK, Creinin MD, Barnhart KT, et al. A phase I comparative postcoital testing study of three concentrations of C31G. Contraception 2004b; 70: 227-231.
31. Mauck CK, Weiner DH, Creinin MD, et al. A randomized Phase I vaginal safety study of three concentrations of C31G vs. Extra Strength Gynol II. Contraception 2004c; 70: 233-240.
32. Peterson L, Nanda K., Opoku BK, et al., SAVVY (C31G) gel for prevention of HIV infection in women: A phase 3, double-blind, randomized, placebo-controlled trial in Ghana. PLos ONE 2007; 2: e1312.
33. Feldblum PJ, Adeiga A, Bakare R, et al. SAVVY vaginal gel (C31G) for prevention of HIV infection: A randomized controlledtrial in Nigeria. PLoS One 2008; 3: e1474.
34. Burke AE, Barnhart K, Jensen JT. Contraceptive efficacy, acceptability, and safety of C31G and nonoxynol-9 spermicidal gels: a randomized controlled trial. Obstet Gynecol 2010; 116: 1265-1273.
35. Fichorova RN, Tucker LD, Anderson DJ. The molecular basis of nonoxynol-9-induced vaginal inflammation and its possiblerelevance to human immunodeficiency virus type 1 transmission. J Infect Dis 2001; 184: 418-418.
36. Fichorova RN, Bajpai M, Chandra N, et al. Interleukin (IL)-1, IL-6, and IL-8 predict mucosal toxicity of vaginal microbicidal contraceptives. Biol Reprod 2004; 71: 761-769.
37. Catalone BJ, Kish-Catalone TM, Budgeon LR, et al: Mouse model of cervicovaginal toxicity and inflammation for preclinical evaluation of topical vaginal microbicides. Antimicrob Agents Chemother 2004; 48: 1837-1847.
38. Wilson SS, Cheshenko N, Fakioglu E, et al: Susceptibility to genital herpes as a biomarker predictive of increased HIV risk: expansion of a murine model of microbicide safety. Antivir Ther 2009; 14: 1113-1132.
39. Zalenskaya IA, Cerocchi OG, Joseph T, et al: Increased COX-2 Expression in Human Vaginal Epithelial Cells Exposed to Nonoxynol-9, a Vaginal Contraceptive Microbicide that Failed to Protect Women from HIV-1 Infection. Am J Reprod Immunol 2011; 65: 569-577.
40. Martin LS, Loskoski SL, McDougal JS. Inactivation of human Tlymphotropic virus type III/lymphadenopathy-associated virus byformaldehyde-based reagents. Appl Environ Microbiol 1987; 53: 708-709.
41. Ongradi J, Ceccherini-Nelli L, Pistello M, et al. Acid sensitivity of cell-free and cell-associated HIV-1: clinical implications. AIDSRes Hum Retroviruses 1990; 6: 1433-1466.
42. Anderson DJ, Yunis EJ. Trojan Horse leukocytes in AIDS. N Engl J Med 1983; 309: 984-985.
43. Quayle AJ, Zu C, Mayer KH, et al. T lymphocytes and macrophages, but not motile spermatozoa, are a significant source of human immunodeficiency virus in semen. J Infect Dis 1995; 176: 960-968.
44. Khanna KV, Whaley KJ, Zeitlin L, et al. Vaginal transmission of cell-associated HIV-1 in the mouse is blocked by a topical, membrane-modifying agent. J Clin Invest 2002; 109: 205-211.
45. Sallé B, Brochard P, Bourry O, et al. Infection of macaques after vaginal exposure to cell-associated simian immunodeficiency virus. J Infect Dis 2010; 202: 337-344.
46. Olmsted SS, Khanna KV, Ng EM, et al. Low pH immobilizes and kills human leukocytes and prevents transmission of cell-associated HIV in a mouse model. BMC Infect Dis 2005; 5: 79.
47. Zeitlin L, Hoen TE, Achilles SL, et al. Tests of Buffergel for contraception and prevention of sexually transmitted diseases in animal models. Sex Transm Dis 2001; 28: 417-423.
48. Achilles SL, Shete PB, Whaley KJ, et al. microbicide efficacy and toxicity tests in a mouse model for vaginal transmission ofChlamydia trachomatis. Sex Transm Dis 2002; 29: 655-664.
49. Spencer SE, Valentin-Bon IE, Whaley K, et al. Inhibition of Neisseria gonorrhoeae genital tract infection by leading-candidate topical microbicides in a mouse model. J Infect Dis 2004; 189: 410-419.
50. Tuyama AC, Cheshenko N, Carlucci MJ, et al. ACIDFORM inactivates herpes simplex virus and prevents genital herpes in a mouse model: optimal candidate for microbicide combinations. J Infect Dis 2006; 194: 795-803.
51. Olmsted SS, Dubin NH, Cone RA, et al. The rate at which human sperm are immobilized and killed by mild acidity. FertilSteril 2000; 73: 687-693.
52. Atashili J, Poole C, Ndumbe PM, et al. Bacterial vaginosis and HIV acquisition: a meta-analysis of published studies. AIDS 2008; 22: 1493-1501.
53. Nagot N, Ouedraogo A, Defer MC, et al. Association between bacterial vaginosis and Herpes simplex virus type-2 infection: implications for HIV acquisition studies. Sex Transm Infect 2007; 83: 365-368.
54. Gallo MF, Warner L, Macaluso M, et al. Risk factors for incident herpes simplex type 2 virus infection among women attending a sexually transmitted disease clinic. Sex Transm Dis 2008; 35: 679-685.
55. Cherpes TL, Meyn LA, Krohn MA, et al. Association between acquisition of herpes simplex virus type 2 in women and bacterial vaginosis. Clin Infect Dis 2003; 37: 319-325.
56. Kaul R, Nagelkerke NJ, Kimani J, et al. Prevalent herpes simplex virus type 2 infection is associated with altered vaginal flora and an increased susceptibility to multiple sexually transmitted infections. J Infect Dis 2007; 196: 1692-1697.
57. Garg S, Anderson RA, Chany CJ, et al. Properties of a new acid-buffering bioadhesive vaginal formulation (ACIDFORM). Contraception 2001; 64: 67-75.
58. Fletcher PS, Harman SJ, Boothe AR, et al. Preclinical evaluation of lime juice as a topical microbicide candidate. Retrovirology 2008;11; 5: 3.
59. Mauck CK, Ballagh SA, Creinin MD, et al. Six-day randomized safety trial of intravaginal lime juice. J Acquir Immune DeficSyndr 2008; 49: 243-250.
60. Amaral E, Faúndes A, Zaneveld L, et al. Study of the vaginal tolerance to Acidform, an acid-buffering, bioadhesive gel. Contraception 1999; 60: 361-366.
61. Schwartz JL, Poindexter A, Schmitz SW, et al. Male tolerance of ACIDFORM gel. Contraception 2005; 71: 443-446.
62. Patton DL, Sweeney YC, Cummings PK et al. Safety and efficacy evaluations for vaginal and rectal use of BufferGel in the macaque model. Sex Transm Dis 2004; 31: 290-296.
63. Mayer KH, Peipert J, Fleming T, et al. Safety and tolerability of BufferGel, a novel vaginal microbicide, in women in the UnitedStates. Clin Infect Dis 2001; 32: 476-482.
64. van De Wijgert J, Fullem A, Kelly C, et al. Phase 1 trial of the topical microbicideBufferGel: safety results from four international sites. J Acquir Immune DeficSyndr 2001; 26: 21-27.
65. Barnhart KT, Rosenberg MJ, Mackay, et al. Contraceptive efficacy of a novel spermicidal microbicide used with a diaphragm: a randomized controlled trial. Obstet Gynecol 2007; 110: 577-586.
66. Abdool Karim SS, Richardson BA, Ramjee G, et al. HIV Prevention Trials Network (HPTN) 035 Study Team. Safety and effectiveness of BufferGel and 0.5% PRO 2000 gel for the prevention of HIV infection in women. AIDS 2011; 25: 957-966.
67. Connor RI. Sensitivity of non-clade B primary HIV-1 isolates to mildly acidic pH. J Acquir Immune DeficSyndr 2006; 43: 499-501.
68. Zeitlin L, Whaley KJ, Hegarty TA, et al. Tests of vaginal microbicides in the mouse genital herpes model. Contraception 1997; 56: 329-335.
69. Ito M, Baba M, Sato A, et al. Inhibitory effect of dextran sulfate and heparin on the replication of human immunodeficiency virus (HIV) in vitro. Antiviral Res 1987; 7: 361-367.
70. Mitsuya H, Looney DJ, Kuno S, et al. Dextran sulfate suppression of viruses in the HIV family: inhibition of virion binding to CD4+ cells. Science 1988; 240: 646-649.
71. Baba M, Nakajima M, Schols D, et al. Pentosan polysulfate, a sulfated oligosaccharide, is a potent and selective anti-HIV agent invitro. Antiviral Res 1988; 9: 335-343.
72. Pearce-Pratt R, Phillips DM: Sulfated polysaccharides inhibit lymphocyte-to-epithelial transmission of human immunodeficiencyvirus-1. Biol Reprod 1996; 54: 173-182.
73. Patton DL, Cosgrove-Sweeney YT, Paul KJ: A summary of preclinical topical microbicide vaginal safety and chlamydial efficacy evaluations in a pigtailed macaque model. Sex Transm Dis 2008; 35: 889-897.
74. Witvrouw M, De Clercq E: Sulfated polysaccharides extracted from sea algae as potential antiviral drugs. Gen Pharmacol 1997; 29: 497-511.
75. Christensen ND, Reed CA, Culp TD, et al: Papillomavirus microbicidal activities of high-molecular-weight cellulose sulfate, dextran sulfate, and polystyrene sulfonate. Antimicrob Agents Chemother 2001; 45: 3427-3432.
76. Anderson RA, Feathergill KA, Diao XH, et al. Preclinical evaluation of sodium cellulose sulfate (Ushercell) as a contraceptive antimicrobial agent. J Androl 2002; 23: 426-448.
77. Saifuddin M, Doncel GF, Tsai L, et al. Intravaginal administration of 6% cellulose sulfate (CS) gel prevented systemic infection in rhesus macaques in a multiple dose R5/X4 SHIV vaginal challenge model. Abstract presented at Microbicides 2008, New Delhi, India, 2008.
78. Mauck C, Weiner DH, Ballagh S, et al. Single and multiple exposure tolerance study of cellulose sulfate gel: a Phase I safety and colposcopy study. Contraception 2001; 64: 383-391.
79. Malonza IM, Mirembe F, Nakabiito C, et al. Expanded Phase I safety and acceptability study of 6% cellulose sulfate vaginal gel. AIDS 2005; 19: 2157-2163.
80. Doh AS, Ngoh N, Roddy R, et al. Safety and acceptability of 6% cellulose sulfate vaginal gel applied four imes per day for 14 days. Contraception 2007; 76: 245-249.
81. Mauck CK, Freziers RG, Walsh TL, et al. Noncomparative contraceptive efficacy of cellulose sulfate gel. Obstet Gynecol 2008; 111: 739-746.
82. Van Damme L, Govinden R, Mirembe FM, et al. Lack of effectiveness of cellulose sulfate gel for the prevention of vaginalHIV transmission. N Engl J Med 2008; 359: 463-472.
83. Halpern V, Ogunsola F, Obunge O, et al. Effectiveness of cellulose sulfate vaginal gel for the prevention of HIV infection: results of a Phase III trial in Nigeria. PLoS One 2008; 3: e3784.
84. Phillips DM: Intravaginal formulations to prevent HIV infection. Perspectives in Drug Discovery and Design 1996; 5: 213-224.
85. Zacharopoulos VR, Phillips DM: Cell-mediated HTLV-I infection of a cervix-derived epithelial cell line. Microb Pathog 1997; 23: 225-233.
86. Zaretzky FR, Pearce-Pratt R, Phillips DM: Sulfated polyanions block Chlamydia trachomatis infection of cervix-derived human epithelia. Infect Immun 1995; 63: 3520-3526.
87. Buck CB, Thompson CD, Roberts JN, et al. Carrageenan is a potent inhibitor of papillomavirus infection. PLoS Pathog 2006; 2: e69.
88. Turville SG, Aravantinou M, Miller T, et al. Efficacy of Carraguard-based microbicides in vivo despite variable in vitro activity. PLoS One 2008; 3: e3162.
89. Dezzutti CS, James VN, Ramos A, et al. In vitro comparison of topical microbicides for prevention of human immunodeficiency virus type 1 transmission. Antimicrob Agents Chemother 2004; 48: 3834-3834.
90. Skoler-Karpoff S, Ramjee G, Ahmed K, et al. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372: 1977-1987.
91. Rusconi S, Moonis M, Merrill DP, et al. Naphthalene sulfonate polymers with CD4-blocking and anti-human immunodeficiencyvirus type 1 activities. Antimicrob Agents Chemother 1996; 40: 234-236.
92. Cheshenko N, Keller MJ, MasCasullo V, et al. Candidate topical microbicides bind herpes simplex virus glycoprotein B and prevent viral entry and cell-to-cell spread. Antimicrob Agents Chemother 2004; 48: 2025-2036.
93. Weber J, Nunn A, O'Connor T, et al. 'Chemical condoms' for the prevention of HIV infection: evaluation of novel agents against SHIV(89.6PD) in vitro and in vivo. AIDS 2001; 15: 1563-1568.
94. Lewis M: Efficacy of PRO 2000 in macaques. Abstract presented at Microbicides 2008, New Delhi, India, 2008.
95. Van Damme L, Wright A, Depraetere K, et al. A phase I study of a novel potential intravaginal microbicide, PRO 2000, in healthy sexually inactive women. Sex Transm Infect 2000; 76: 126-130.
96. Mayer KH, Karim SA, Kelly C, et al. Safety and tolerability of vaginal PRO 2000 gel in sexually active HIV-uninfected andabstinent HIV-infected women. AIDS 2003; 17: 321-329.
97. Kamali A, Byomire H, Muwonge C, et al. A randomised placebocontrolled safety and acceptability trial of PRO 2000 vaginalmicrobicide gel in sexually active women in Uganda. Sex Transm Infect 2010; 86: 222-226.
98. Karim SS, Richardson BA, Ramjee G, et al. Safety and effectiveness of BufferGel and 0.5% PRO 2000 gel for the prevention of HIV infection in women. AIDS 2011; 25: 957-966.
99. McCormack S, Ramjee G, Kamali A, et al. PRO 2000 vaginal gel for prevention of HIV-1 infection (Microbicides DevelopmentProgramme 301): a phase 3, randomised, double-blind, parallelgroup trial. Lancet 2010; 376: 1329-1337.
100. Pirrone V, Wigdahl B, Krebs FC: The rise and fall of polyanionic inhibitors of the human immunodeficiency virus type 1. Antiviral Res 2011; 90: 168-182.
101. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010; 363: 2587-2599.
102. Baeten J, Cellum C, et al. Antiretroviral pre-exposure prophylaxis for HIV-1 prevention among women: The Partners PrEP study. IAS, July 17-20, 2011; abstract MOAX0106, Rome, Italy.
103. Abdool Karim Q, Abdool Karim SS, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010; 329: 1168-1174. doi:10.1126/science.1193748.
104. McCarthy TD, Karellas P, Henderson SA, et al. Dendrimers as drugs: discovery and preclinical and clinical development of dendrimer-based microbicides for HIV and STI prevention. Mol Pharm. 2005; 2: 312-318.
105. Rupp R, Rosenthal SL, Stanberry LR. VivaGel (SPL7013 Gel): a candidate dendrimer-microbicide for the prevention of HIV and HSV infection. Int J Nanomedicine 2007; 2: 561-566.
106. Jiang YH, Emau P, Cairns JS, et al. SPL7013 gel as a topical microbicide for prevention of vaginal transmission of SHIV89.6P in macaques. AIDS Res Hum Retroviruses 2005; 21: 207-13.
107. Chen MY, Millwood IY, Wand H, et al. A randomized controlled trial of the safety of candidate microbicide SPL7013 gel when applied to the penis. J Acquir Immune Defic Syndr 2009; 50: 375-380.
108. O'Loughlin J, Millwood IY, McDonald HM, et al. Safety, tolerability, and pharmacokinetics of SPL7013 gel (VivaGel): a dose ranging, phase I study. Sex Transm Dis 2010; 37: 100-104.
109. Cohen CR, Brown J, Moscicki AB et al. A phase I randomized placebo controlled trial of the safety of 3% SPL7013 Gel (VivaGel®) in healthy young women administered twice daily for 14 d. PLoS One. 2011; 6: e16258.
110. McGowan I, Gomez K, Bruder K, et al. Phase 1 randomized trial of the vaginal safety and acceptability of SPL7013 gel (VivaGel) in sexually active young women (MTN-004). AIDS 2011; 25: 1057-64.
111. Talwar GP, Raghuvanshi P, Mishra R. et al. Polyherbal formulations with wide spectrum antimicrobial activity against reproductive tract infections and sexually transmitted pathogens. Am J Reprod Immunol 2000; 43: 144-151.
112. Joshi SN, Katti U, Godbole S, et al. Phase I safety study of Praneem polyherbal vaginal tablet use among HIV-uninfectedwomen in Pune, India. Trans R Soc Trop Med Hyg. 2005; 99: 769-774.
113. Joglekar NS, Joshi SN, Navlakha SN, et al. Acceptability of Praneem polyherbal vaginal tablet among HIV uninfected women & their male partners in Pune, India-Phase I study. Indian J Med Res 2006; 123: 547-552.
114. Joshi SN, Dutta S, Kumar BK, et al. Expanded safety study of Praneem polyherbal vaginal tablet among HIV-uninfected women in Pune, India: a phase II clinical trial report. Sex Transm Infect 2008; 84: 343-347.
115. Joglekar NS, Joshi SN, Deshpande SS, et al. Acceptability and adherence: findings from a Phase II study of a candidate vaginal microbicide, 'Praneem polyherbal tablet', in Pune, India. Trans R Soc Trop Med Hyg 2010; 104: 412-415.
116. Salhan S, Tripathi V, Sehgal R, et al. A phase II randomized controlled trial to evaluate the safety and efficacy of Praneem polyherbal vaginal tablets compared with betadine vaginal pessary in women with symptoms of abnormal vaginal discharge. Asia Pac J Public Health 2009; 21: 461-468.
117. Kumel G, Schrader S, Zentgraf H, et al. The mechanism of the antiherpetic activity of zinc sulphate. J Gen Virol 1990; 71: 2989-2997.
118. Haraguchi Y, Sakurai H, Hussain S, et al. Inhibition of HIV-1 infection by zinc group metal compounds. Antivir Res 1999; 43: 123-133.
119. Arens M, Travis S. Zinc salts inactivate clinical isolates of herpes simplex virus in vitro. J Clin Microbiol 2000; 38: 1758-1762.
120. Bourne N, Stegall R, Montano R, Meador M, et al. Efficacy and toxicity of zinc salts as candidate topical microbicides against vaginal herpes simplex virus type 2 infection. Antimicrob Agents Chemother 2005; 49: 1181-1183.
121. Geist FC, Bateman JA, Hayden FG. In vitro activity of zinc salts against human rhinoviruses. Antimicrob Agents Chemother 1987; 31: 622-624.
122. Lazarczyk M, Favre M. Role of Zn2+ ions in host-virus interactions. J Virol 2008; 82: 11486-11494.
123. Prasad AS, Beck FW, Bao B, et al. Duration and severity of symptoms and levels of plasma interleukin-1 receptor antagonist, soluble tumor necrosis factor receptor, and adhesion molecules in patients with common cold treated with zinc acetate. J Infect Dis 2008; 197: 795-802.
124. Suara RO, Crowe JE, Jr. Effect of zinc salts on respiratory syncytial virus replication. Antimicrob Agents Chemother 2004; 48: 783-790.
125. Zhang ZY, Reardon IM, Hui JO, et al. Zinc inhibition of renin and the protease from human immunodeficiency virus type 1.Biochemistry 1991;30: 8717-8721.
126. Shankar AH, Prasad AS. Zinc and immune function: the biological basis of altered resistance to infection. Am J Clin Nutr 1998; 68:447S-463S.
127. Rink L, Kirchner H. Zinc-altered immune function and cytokine production. J Nutr 2000; 130: 1407S-1411S.
128. Li Q, Estes JD, Schlievert PM, et al. Glycerol monolaurate prevents mucosal SIV transmission. Nature 2009; 458: 1034-1038.
129. Krieger JN, Rein MF. Zinc sensitivity of Trichomonas vaginalis: in vitro studies and clinical implications. J Infect Dis 1982; 146: 341-345.
130. Andrews BJ, Mylvaganam H, Yule A. Sensitivity of Trichomonas vaginalis, Tritrichomonas foetus and Giardia intestinalis tobacitracin and its zinc salt in vitro. Trans R Soc Trop Med Hyg 1994; 88: 704-706.
131. Kilmarx PH, Blanchard K, Chaikummao S, et al. A randomized, placebo-controlled trial to assess the safety and acceptability of use of carraguard vaginal gel by heterosexual couples in Thailand. Sex Transm Dis 2008; 35: 226-232.
132. Kilmarx PH, van de Wijgert JH, Chaikummao S, et al. Safety and acceptability of the candidate microbicide Carraguard in ThaiWomen: findings from a Phase II Clinical Trial. J Acquir Immune Defic Syndr 2006; 43: 327-334.
133. Cummins JE, Jr., Guarner J, Flowers L, et al. Preclinical testing of candidate topical microbicides for anti-human immunodeficiencyvirus type 1 activity and tissue toxicity in a human cervical explant culture. Antimicrob Agents Chemother 2007; 51: 1770-1779.
134. Whitehead SJ, Kilmarx PH, Blanchard K, et al. Acceptability of Carraguard vaginal gel use among Thai couples. AIDS 2006; 20:2141-2148.
135. Martin S, Blanchard K, Manopaiboon C, et al. Carragaurd acceptability among men and women in a couples study in Thailand. J Womens Health 2010; 19: 1-7.
136. McLean CA, van de Wijgert JH, Jones HE, et al. HIV genital shedding and safety of Carraguard use by HIV-infected women: acrossover trial in Thailand. Aids 2010; 24: 717-722.
137. Fernández-Romero JA, Thorn M, Titchen K, et al. Carrageenan/MIV-150 (PC-815), A Combination Microbicide. Sexually Transmitted Diseases 2007; 34: 9-14.
138. Kenney J, Aravantinou M, Singer R, et al. An antiretroviral/zinc combination gel provides 24 hours of complete protection against vaginal SHIV infection in macaques. PLoS One 2011; 6: e15835.
139. Veazey RS, Ketas TA, Klasse PJ, et al. Tropism-independent protection of macaques against vaginal transmission of three SHIVs by the HIV-1 fusion inhibitor T-1249. Proc Natl Acad Sci USA 2008; 105: 10531-10536.
140. Veazey RS, Shattock RJ, Pope M, et al. Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat Med 2003; 9: 343-346.
141. Veazey RS, Klasse PJ, Schader SM, et al. Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion. Nature 2005; 438: 99-102.
142. Lederman MM, Veazey RS, Offord R, et al. Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. Science 2004; 306: 485-487.
143. Parikh UM, Dobard C, Sharma S, et al. Complete protection from repeated vaginal simian-human immunodeficiency virus exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine. J Virol 2009; 83: 10358-10365.
144. Cranage M, Sharpe S, Herrera C, et al. Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel. PLoS Med 2008; 5: e157; discussion e157.
145. Veazey RS, Ling B, Green LC, et al. Topically applied recombinant chemokine analogues fully protect macaques from vaginal simian-human immunodeficiency virus challenge. J Infect Dis 2009; 199: 1525-1527.
146. Roberts JN, Buck CB, Thompson CD, Kines R, Bernardo M, et al. (2007) Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat Med 2007; 13: 857-861.
147. Marais D, Gawarecki D, Allan B, et al. The effectiveness of Carraguard, a vaginal microbicide, in protecting women against high risk Human Papillomavirus infection. Antiviral Therapy 2007, In Press.
148. Thurman AR, Clark MR, Doncel GF. Multipurpose Prevention Technologies: Biomedical Tools to Prevent HIV-1, HSV-2, and Unintended Pregnancies. Infect Dis Obstet Gynecol 2011; 2011: 429403.
149. Moore MD, Cookson J, Coventry VK, et al. Protection of HIV neutralizing aptamers against rectal and vaginal nucleases: implications for RNA-based therapeutics. J BiolChem 2011; 286: 2526-2535.
150. Moore MD, Bunka DH, Forzan M, et al. Generation of neutralizing aptamers against herpes simplex virus type 2: potential componentsof multivalent microbicides. J Gen Virol 2011; 92: 1493-1499.
151. Wheeler LA, Trifonova R, Vrbanac V, et al. Inhibition of HIV transmission in human cervicovaginal explants and humanized mice using CD4 aptamer-siRNA chimeras. J Clin Invest. 2011; 121: 2401-2412.
152. Bobardt MD, Chatterji U, Schaffer L, et al. Syndecan-Fc hybrid molecule as a potent in vitro microbicidal anti-HIV-1 agent. Antimicrob Agents Chemother 2010; 54: 2753-2766.
153. Zeitlin L, Whaley KJ. Microbicides for preventing transmission of genital herpes. Herpes 2002; 9: 4-9.
154. Sexton A, Harman S, Shattock RJ, et al. Design, expression, and characterization of a multivalent, combination HIV microbicide. FASEB J 2009; 23: 3590-3600.
155. Walker LM, Huber M, Doores KJ, et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 2011 Aug 17. doi: 10.1038/nature10373.
156. Mori T, O'Keefe BR, Sowder RC, et al. Isolation and characterization of griffithsin, a novel HIV-inactivating protein, from the red alga Griffithsia sp. J Biol Chem 2005; 280: 9345-53.
157. Cole AM, Patton DL, Rohan LC, et al. The formulated microbicide RC-101 was safe and antivirally active following intravaginal application in pigtailed macaques. PLoS One. 2010; 5: e15111.